Journey Medical Corporation DERM
Regular-session close
After hours · Nov 19, 6:56 PM ET
- YTD
- -53.96%
- 1 year
- -53.59%
5D -0.73 (-16.94%)
- Market cap
- 100.22M
- Revenue (ttm)
- 57.77M
- Profit margin
- -31.74%
- EPS (ttm)
- -0.18
- Shares out
- 14.89M
- Forward P/E
- -75.83
- YTD return
- -53.96%
- 1-year return
- -53.59%
- Volume
- 215.48K
- Avg volume
- 192.61K
- Open
- 3.77
- Previous close
- 3.69
- Day's range
- 3.52 – 3.79
- 52-week range
- 3.40 – 9.56
- Price target
- 10.00 (+181.7%)
- 50-day average
- 5.50
Key statistics
- 200-day average
- 4.83
- Enterprise value
- 96.37M
- Price / sales
- 1.65
- Price / book
- 8.63
- Revenue growth
- -57.60%
- Free cash flow
- -25.48M
- Total cash
- 22.46M
- Total debt
- 21.07M
- Return on equity
- -129.58%
- Short % of float
- 1.71%
Fundamental scorecard
8 of 25 checks passed on DERM’s reported financials
8of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.17 | -0.12 | +0.05 | +29.41% |
| Aug 12, 2024 | Jun 1, 2024 | -0.15 | -0.17 | -0.02 | -13.33% |
| Aug 12, 2024 | Jun 1, 2024 | -0.15 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.26 | -0.53 | -0.27 | -103.85% |
| May 13, 2024 | Mar 1, 2024 | -0.26 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | 0.00 | -0.12 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 16, 2024 | Alliance Global Partners | init | — | Buy |
| Sep 7, 2023 | B. Riley Securities | reit | Buy | Buy |
| Jul 12, 2023 | B. Riley Securities | main | Buy | Buy |
| May 23, 2023 | B. Riley Securities | main | Buy | Buy |
| Mar 30, 2023 | B. Riley Securities | reit | — | Buy |
| Feb 25, 2022 | Cantor Fitzgerald | init | — | Overweight |
About Journey Medical Corporation
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- journeymedicalcorp.com
News
B. Riley Securities Reiterates Buy on Journey Medical, Lowers Price Target to $13
Journey Medical Corporation (DERM) Q3 2026 Earnings Call Transcript Journey Medical Q3 EPS $(0.05) Misses $(0.01) Estimate, Sales $18.967M Miss $20.321M Estimate
Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026 HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target
Vireo Growth (OTCMKTS:VREOD) vs. Journey Medical (NASDAQ:DERM) Critical Contrast
Journey Medical: A Small Pharma With A Large Growth Opportunity
Journey Medical Corporation to Participate in September 2026 Investor Conferences
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
Your note
Sign in to keep a note on DERM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENESCH JOSEPH | Chief Financial Officer | Sale | Jul 31, 2024 | 47,331 |
| HERSKOWITZ NEIL | Director | Stock Award(Grant) | Jul 7, 2024 | 81,445 |
| MARAOUI CLAUDE | Chief Executive Officer | Purchase | Mar 21, 2024 | 2,163,430 |
| PALEY JEFFREY | Director | Sale | Nov 27, 2023 | 70,727 |
| PEARCE MICHAEL COOPER | Director | Stock Award(Grant) | Jul 18, 2024 | 30,000 |
| ROSENWALD LINDSAY A | Director | Stock Award(Grant) | Jul 7, 2024 | 330,443 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.18% | 325,171 | 1.48M | Sep 29, 2024 |
| Cambridge Investment Research Advisors Inc. | 2.11% | 314,450 | 1.43M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.80% | 268,200 | 1.22M | Sep 29, 2024 |
| American Financial Group Inc. | 1.21% | 180,000 | 819.00K | Sep 29, 2024 |
| Envestnet Asset Management | 0.74% | 109,586 | 498.62K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.73% | 108,435 | 493.38K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.42% | 211,446 | 962.08K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.73% | 109,083 | 496.33K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 57,238 | 260.43K | Oct 30, 2024 |
| World Funds Tr-Perkins Discovery Fund | 0.15% | 22,000 | 100.10K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 18,124 | 82.46K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.12% | 17,985 | 81.83K | Oct 30, 2024 |
